Fundraising Fox
Evommune
Palo Alto, US · Founded 2020 · 67 employees on LinkedIn · 11 known investors
Find your way into Evommune
Sign up to see every warm intro you have to Evommune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Evommune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Founders & leadership
Evommune was founded in 2020 by Luis Pena.
JD
Janice DrewNamed on SEC filing
DC
David CohenNamed on SEC filing
GM
Gregory MossNamed on SEC filing
EB
Eugene BauerNamed on SEC filing
FB
Francois BeaubienNamed on SEC filing
JP
Jeegar PatelNamed on SEC filing
BM
Benjamin McGrawNamed on SEC filing
Board
RH
Robert HopfnerBoard director
DD
FV
YY
Investors · 11
Andera Partnerslisted by Andera PartnersParis
How we know: Andera Partners's portfolio page · Not right? Tell us
Avego BioScience Capitallisted by Avego BioScience CapitalAlpharetta
How we know: Avego BioScience Capital's portfolio page · Not right? Tell us
.jpeg){kind=logo}
B Capital Grouplisted by B Capital GroupSan Francisco · $10M – $50M
How we know: B Capital Group's portfolio page · the VCSheet dataset · Not right? Tell us
FemHealth Ventureslisted by FemHealth VenturesShort Hills
How we know: FemHealth Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Longwood Fundlisted by Longwood FundBoston
How we know: Longwood Fund's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco
How we know: Pivotal Life Sciences's portfolio page · a partner's Signal profile · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
RA Capitallisted by RA CapitalBostonvia Derek DiRocco · board
How we know: RA Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
EQT Life SciencesinferredAmsterdam · $11M – $66Mvia Felice Verduyn - Van Weegen · board
How we know: board seat on SEC Form D · Not right? Tell us
JMI EquityreportedSan Diego · $25M – $250M
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$392.3M disclosed across 5 of 6 rounds · 2020–2026
▶$57.5MraisedJan 2025 · 16 investors · OtherRule 506(b)
▶$57.5MraisedJan 2025 · 16 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Felice Verduyn-van WeegenDirector
- Janice DrewExecutive Officer
- Benjamin McGrawDirector
- Eugene BauerExecutive Officer, Director
- Derek DiRoccoDirector
- Luis PenaExecutive Officer, Director
- Kyle CarverExecutive Officer
- Gregory MossExecutive Officer
- Jeegar PatelExecutive Officer
- David CohenDirector
- Robert HopfnerDirector
- Francois BeaubienDirector
- Yuexin YuDirector
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$81.8MraisedJan 2025 · 10 investors · OtherRule 506(b)
▶$81.8MraisedJan 2025 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Janice DrewExecutive Officer
- David CohenDirector
- Robert HopfnerDirector
- Derek DiRoccoDirector
- Gregory MossExecutive Officer
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Francois BeaubienDirector
- Jeegar PatelExecutive Officer
- Yuexin YuDirector
- Benjamin McGrawDirector
- Luis PenaExecutive Officer, Director
- Kyle CarverExecutive Officer
- Offering amount
- $84.4M
- Amount sold
- $81.8M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$115.5MraisedJan 2025 · 25 investors · OtherRule 506(b)
▶$115.5MraisedJan 2025 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Derek DiRoccoDirector
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Robert HopfnerDirector
- Kyle CarverExecutive Officer
- David CohenDirector
- Gregory MossExecutive Officer
- Francois BeaubienDirector
- Benjamin McGrawDirector
- Jeegar PatelExecutive Officer
- Yuexin YuDirector
- Janice DrewExecutive Officer
- Luis PenaExecutive Officer, Director
- Offering amount
- $115.5M
- Amount sold
- $115.5M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$12.5MraisedJan 2025 · 18 investors · OtherRule 506(b)
▶$12.5MraisedJan 2025 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Gregory MossExecutive Officer
- Yuexin YuDirector
- Jeegar PatelExecutive Officer
- Francois BeaubienDirector
- Robert HopfnerDirector
- Kyle CarverExecutive Officer
- Luis PenaExecutive Officer, Director
- David CohenDirector
- Derek DiRoccoDirector
- Benjamin McGrawDirector
- Janice DrewExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Primmune TherapeuticsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
NexImmuneNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Companies working in the same space as Evommune.
In the news
Frequently asked questions
- What does Evommune do?
- Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
- Who founded Evommune?
- Evommune was founded by Luis Pena in 2020.
- Who are Evommune's investors?
- Evommune's investors include Andera Partners, Avego BioScience Capital, B Capital Group, B4 Capital, Beiersdorf Innovation Fund, FemHealth Ventures, Longwood Fund, Pivotal Life Sciences and 3 more.
- How much funding has Evommune raised?
- Evommune has disclosed $392.3M raised across 5 of its 6 known rounds.
- Where is Evommune headquartered?
- Evommune is headquartered in Palo Alto, US.